The Top Women Leaders in Healthcare Technology of 2025

The Healthcare Technology Report is pleased to announce The Top Women Leaders in Healthcare Technology of 2025. Across diagnostics, data infrastructure, patient services, and clinical development, these women are driving real operational and strategic progress inside some of the most complex corners of healthcare. Whether building AI-enabled platforms, leading compliance across state-by-state insurance rules, or navigating FDA-regulated product portfolios, they’re translating innovation into systems that work at the point of care and deep inside the enterprise.

This year’s awardees include C-suite executives, co-founders, and functional leaders operating across startup, nonprofit, and global enterprise settings. Many have helped guide their organizations through major clinical trials, fundraising rounds, platform expansions, or product rollouts in the past year—milestones that reflect the depth and durability of their leadership. Collectively, they offer a clearer view of how progress actually happens in a sector shaped by scientific rigor, policy shifts, and patient-level complexity.

Among them, Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher, guided the company to $24.6 billion in annual revenue while overseeing regulatory achievements such as FDA clearance of the Cepheid GI Panel. At AmplifyMD, CEO and Co-Founder Meena Mallipeddi led a Series B round backed by Forerunner, Greylock, and Memorial Hermann to deepen AI-driven clinical workflows and expand specialty coverage. And Dominique Demolle, CEO and Co-Founder of Cognivia, launched an AI platform that achieved 93% accuracy in predicting trial dropouts—offering sponsors a new lever to reduce delays and strengthen study integrity.

Carefully selected through a thorough review of each individual’s contributions, this year’s awardees represent the strength and range of leadership driving healthcare technology forward. Please join us in recognizing The Top Women Leaders in Healthcare Technology of 2025.

 

Anne-Renee Hartman
Company: Adela
Title: Chief Medical Officer & Co-Founder

Anne-Renee Hartman is Chief Medical Officer and Co-Founder of Adela, where she leads clinical strategy for the company’s blood-based approach to molecular residual disease monitoring and early cancer detection. Since co-founding Adela in 2020, Anne-Renee has helped shape its tissue-agnostic testing platform, designed to support treatment decisions when tumor tissue is unavailable.

In May 2025, Adela presented clinical data at the American Society of Clinical Oncology Annual Meeting on its genome-wide methylome enrichment test, including findings on predicting disease progression and identifying early non-responders to immunotherapy across multiple solid tumors. The company also said it planned to commercialize its MRD test for recurrence monitoring in patients treated with curative intent for head and neck cancer.

Before Adela, Anne-Renee held senior clinical leadership roles at GRAIL and Myriad Genetics, where she built large oncology development programs and led dozens of clinical trials. She earned her MD from the University of Michigan Medical School after completing a bachelor’s degree in molecular biology at Princeton University.

 

Lauren Bennett
Company: Aeroflow Health
Title: President

Lauren Bennett is President of Aeroflow Health, overseeing national operations for the Asheville-based company. Founded in 2001, Aeroflow helps patients access insurance-covered medical equipment and support services.

Aeroflow reached a major milestone in July 2025 by launching a nationwide partnership with Cigna, expanding access to telehealth nutrition services for new mothers and patients managing diabetes and other chronic conditions. The program connects Cigna members with registered dietitians for personalized care delivered entirely from home.

Lauren joined Aeroflow in 2014 and has advanced through nearly every operational level of the organization, including director of sales operations, VP of Aeroflow Sleep, chief operating officer, and now President. Her experience spans medical billing, revenue cycle management, automation, and large-scale process improvement.

Known for building high-trust teams and scalable systems, Lauren focuses on improving experiences for patients, providers, and health plans. She earned her bachelor’s degree from the Medical University of South Carolina.

 

Meena Mallipeddi
Company: AmplifyMD
Title: Co-Founder & Chief Executive Officer

Meena Mallipeddi is Co-Founder and CEO of AmplifyMD, where she leads the company’s mission to expand specialty care access across emergency, inpatient, and outpatient settings through an AI-enabled, multispecialty virtual care platform. She co-founded AmplifyMD in 2019 after a career spanning healthcare, technology, and finance, with early roles in consulting and investment research before moving into healthcare entrepreneurship.

In September 2025, AmplifyMD raised a Series B round led by Forerunner Ventures, with participation from F-Prime, Greylock, Tau Ventures, and Memorial Hermann Health System. The funding is being used to deepen the company’s AI-driven clinical workflows, expand hospital partnerships, and scale specialty coverage across more care settings nationwide. Today, AmplifyMD supports more than 15 medical specialties, helping health systems reduce wait times, lower operational costs, and improve access to care.

Before launching AmplifyMD, Meena worked as an equity analyst and private investor focused on healthcare and technology. She holds a bachelor’s degree in international relations from Stanford University and a master’s degree in technology policy from the University of Cambridge.

 

Leigh Ann Furr
Company: Angle Health
Title: Director of Compliance

Leigh Ann Furr is the Director of Compliance at Angle Health, playing a central role in embedding regulatory rigor into the company’s AI-enabled health benefits platform. With over 25 years of experience across health insurance, managed care, and privacy programs, Leigh Ann works closely with product and engineering teams to support compliant quoting, onboarding, administration, and member engagement across Angle’s unified carrier, TPA, and MGA model within a single connected system.

Angle Health raised a $134 million oversubscribed Series B in December 2025 to scale its platform nationwide, bringing total funding to nearly $200 million as the company expanded across 44 states. In her role as Director of Compliance, Leigh Ann supports that scale by translating state and federal requirements into repeatable policies and controls that help reduce regulatory risk as the platform and operations grow.

Before joining Angle, Leigh Ann led corporate compliance and data privacy programs at Maestro Health and held earlier roles in quality improvement and client services. She earned a bachelor’s degree in biology from the University of North Carolina at Charlotte.

 

Neda Safarzadeh
Company: Arcturus Therapeutics
Title: Vice President, Head of Investor Relations, Public Relations & Marketing

Neda Safarzadeh is Vice President and Head of Investor Relations, Public Relations, and Marketing at Arcturus Therapeutics. She leads the company’s communications with investors, partners, and the broader market, translating complex RNA science into clear, consistent messaging. Neda joined Arcturus in its early years and has supported its growth from a startup into a publicly traded mRNA medicines and vaccines company headquartered in San Diego.

A notable 2025 milestone for the company came in November, when Arcturus reported third-quarter financial results and detailed pipeline progress, including interim Phase 2 clinical data for ARCT-032 in cystic fibrosis and continued advancement of ARCT-810 for OTC deficiency. Neda leads the investor relations and public relations work around disclosures like these, including earnings communications and investor materials.

Neda also leads global digital and brand strategy, including corporate and clinical websites, and oversees multimedia content and conference communications. Before Arcturus, she was a senior scientist at Nitto Denko, where she co-invented a U.S. patent for RNA delivery systems. She studied chemical engineering at UC San Diego.

 

Maeve McQuade
Company: August Bioservices
Title: Senior Director of CDMO Business Development

Maeve McQuade is the Senior Director of CDMO Business Development at August Bioservices, where she leads commercial partnerships for the company’s sterile injectable manufacturing programs. Having over a decade of experience across contract development and manufacturing, Maeve focuses on helping pharmaceutical and biotech clients translate complex needs into practical, scalable manufacturing solutions.

August Bioservices marked a major growth milestone in 2025, reporting a 77% revenue increase year over year while completing a $64.7 million campus expansion in Nashville to significantly increase manufacturing capacity. As the company works with 40+ customers and scales toward larger batch production, Maeve plays a key role in securing new programs and structuring partnerships that support both clinical and commercial supply.

Before joining August, Maeve held business development roles at Curia, Emergent BioSolutions, Pace Analytical Life Sciences, and Boston Institute of Biotechnology, building experience across development services, GMP testing, and biologics manufacturing. She holds a bachelor’s degree in chemistry from the College of the Holy Cross.

 

Robin Cowie
Company: Biodesix
Title: Chief Financial Officer

Robin Cowie is the Chief Financial Officer of Biodesix, overseeing finance, investor relations, legal, IT, reimbursement strategy, and operational functions. She supports the company’s growth as a public diagnostics business through capital planning, reporting, and cross-functional operations. Robin joined Biodesix in 2011 and became CFO in 2017, with experience spanning corporate finance, government policy, payer relations, and health economics.

In July 2025, Biodesix completed patient enrollment for ALTITUDE, its prospective randomized clinical utility study evaluating Nodify Lung testing in patients with newly identified low-to-moderate risk lung nodules. The same year, the company reported accelerating revenue growth driven by rising Lung Diagnostics test volumes and expanding reimbursement.

Before Biodesix, Robin led payer and government relations at Precision Therapeutics and earlier worked as a laboratory researcher at the University of Pittsburgh Medical Center. She holds a bachelor’s degree in molecular biology from the University of Pittsburgh and an MBA in finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Robin also serves on the board of the Colorado BioScience Association.

 

Paula Richmond
Company: Breg
Title: General Counsel & Chief Compliance Officer

Paula Richmond is General Counsel and Chief Compliance Officer at Breg, overseeing legal, compliance, and audit. She joined Breg in 2014 and advises on governance, risk management, and regulatory readiness across the company’s orthopedic care platform spanning bracing, cold therapy, technology, and clinical services.

In 2025, Breg reported serving a broad network of clinics and providers and reaching nearly two million patients annually. Within that operating scale, Paula’s work focuses on maintaining compliant contracting and business practices, strengthening audit and oversight processes, and supporting product and operational teams as offerings expand.

Before Breg, Paula served as VP of legal and regulatory affairs at United Orthopedic Group and earlier as attorney and compliance officer for St. Jude Medical’s Neuromodulation Division. Her career spans healthcare law, regulatory affairs, and corporate compliance. Paula holds a bachelor’s degree from Texas A&M University and an MBA from SMU’s Cox School of Business. 

 

Gabrielle Carr
Company: Breg
Title: Vice President, Strategy & Financial Planning and Analysis

Gabrielle Carr is Vice President of Strategy and Financial Planning & Analysis at Breg, leading enterprise planning, forecasting, and performance analytics. With more than 16 years at the company, she partners with executive leadership on long-range strategy, capital planning, and operating decisions.

In 2025, Breg continued expanding its orthopedic care platform across a large clinic and provider network, with operations spanning multiple countries and care settings. Gabrielle supports that scale through the planning cadence—building revenue, margin, and cash-flow models, translating priorities into budgets, and tracking performance against targets to inform investment and resourcing decisions.

Promoted to VP in April 2024, Gabrielle most recently led the creation of a five-year strategic plan following an ownership transition, refocusing the business on long-term growth and profitability. She has also been deeply involved in M&A, leading financial due diligence and integration work. 

Earlier in her career, she spent a decade in sales operations, managing territory design, pricing policy, compensation programs, and acquisition-driven sales-force integrations. Gabrielle earned her bachelor’s degree in industrial management from the Georgia Institute of Technology.

 

Lee Ann Fachko
Company: Burlington Medical
Title: Chief Executive Officer

Lee Ann Fachko is the CEO of Burlington Medical, where she leads the company’s mission to protect healthcare providers through radiation safety apparel and accessories designed and manufactured in Newport News, Virginia. Since stepping into the CEO role in 2022, Lee Ann has guided Burlington’s evolution as a global radiation protection provider, building on earlier leadership roles spanning sales, operations, and executive management.

In November 2025, Burlington Medical was awarded a national group purchasing agreement with Premier, Inc. for radiation protection products. Lee Ann pointed to the agreement as a way to expand access to Burlington’s protective equipment through Premier’s member network, supporting clinical teams exposed to scatter radiation in fluoroscopy, interventional radiology, and other imaging settings.

Lee Ann joined Burlington in 2018 and advanced from SVP of sales and marketing to interim CEO, SVP of global operations, president, and ultimately CEO. Her career also includes leadership roles at Beekley Medical and more than a decade at Invitrogen, where she served as director of customer service. She earned a bachelor’s degree in accounting from the State University of New York at Fredonia. 

 

Jing Huang
Company: CareDx
Title: Chief Data & AI Officer

Jing Huang is the Chief Data & AI Officer at CareDx. She leads data science and AI work across the company’s transplant diagnostics and digital health platforms, drawing on more than two decades of experience in statistics, genomics, clinical research, and machine learning to translate complex data into tools that improve clinical utility, operational efficiency, and patient care at scale.

CareDx closed 2025 with approximately $380 million in revenue, including continued growth in testing services and patient and digital solutions. Jing’s work supports this progress by advancing AI-enabled models and analytics that help clinicians manage transplant patients more precisely while strengthening CareDx’s data-driven ecosystem.

Jing earned her bachelor’s degree in statistics and probability from Peking University, followed by a PhD in statistics and a master’s degree in epidemiology from Stanford University. She has co-authored more than 30 peer-reviewed publications and is a co-inventor on over 20 patent filings. Beyond CareDx, Jing serves as founding president of DahShu, a nonprofit dedicated to data science research and education.

 

Athena Uzzo
Company: Claritas Rx
Title: Senior Vice President, Customer Experience

Athena Uzzo is the Senior Vice President of Customer Experience at Claritas Rx, leading teams that help life sciences companies pinpoint where patient access and adherence break down. With 20 years in healthcare technology, Athena brings experience across early discovery, clinical trials, and commercial data operations, connecting analytics, services, and delivery to support the patient journey.

Athena has led commercial and operations functions across growth-stage healthcare technology companies, with a background in clinical trial management, software implementation, and customer support. She builds scalable delivery processes, partners with product and engineering teams, and uses customer experience data and process improvement methods to drive measurable operational gains.

Before Claritas Rx, Athena led customer success at Core Informatics (acquired by Thermo Fisher Scientific) and held clinical and commercial leadership roles at Cogstate and M2S. She earned a bachelor’s degree in chemistry from Boston University and a master’s degree in pharmacology and toxicology from Dartmouth College.

 

Malissa Bennett
Company: CodaMetrix
Title: Chief Revenue & Operations Officer

Malissa Bennett serves as Chief Revenue & Operations Officer at CodaMetrix, where she leads go-to-market strategy, customer success, and commercial operations. She helps drive adoption of the company’s CMX CARE platform across U.S. health systems. With nearly three decades of experience spanning healthcare technology, operations, and advisory services, Malissa focuses on building scalable teams and partnerships that turn AI innovation into real operational impact for providers.

In 2025, she helped guide CodaMetrix through a major growth phase, including continued expansion beyond 30 health system partners in 27 states. This was followed by the June introduction of CMX CARE as a contextual coding automation platform and a new Emergency Department solution, which marked a significant step in CodaMetrix’s enterprise strategy.

Before joining CodaMetrix, Malissa held senior leadership roles at Optum, where she opened new markets and advised large health systems nationwide, and supported Curation Health through rapid growth and acquisition by Reveleer. She earned a bachelor’s degree in biology from Samford University and a master’s degree in humanities from the University of Chicago. 

 

Dominique Demolle
Company: Cognivia
Title: Chief Executive Officer

Dominique Demolle is the CEO and Co-Founder of Cognivia, leading the company’s work to improve clinical trial performance by combining machine learning with quantified patient psychology. Drawing on decades in drug development, Dominique brings a practical lens shaped by senior roles at Eli Lilly, including associate director of global early phase operations.

Dominique guided Cognivia to a major milestone in October 2025 with the release of Cognivia Signal, an AI platform designed to predict patient dropout risk in clinical trials. Validated in a Type 1 diabetes study, the software demonstrated 93% accuracy in identifying patients likely to leave a trial. This gives sponsors a chance to intervene earlier, reduce costly delays, and protect study integrity. Under Dominique’s leadership, this launch marked an important step toward making patient behavior a measurable, actionable part of trial design.

Dominique earned her PhD in biochemistry from the Free University of Brussels, following early research work that led her into clinical pharmacology and global operations leadership. Today, she guides Cognivia’s strategy and partnerships, focused on addressing real-world challenges like nonadherence, placebo response, and patient heterogeneity.

 

Mariana Vaschetto
Company: Collaborative Drug Discovery
Title: Head of Operations

Mariana Vaschetto leads operations for EMEA and LATAM at Collaborative Drug Discovery and drives global collaborations from the company’s European office. She works with research organizations using CDD Vault to manage and share scientific data, supporting cross-border teams across pharma, biotech, and academic settings.

Before joining CDD, Mariana served as VP of strategic partnerships, sales, and marketing at Dotmatics and held similar executive roles at PerkinElmer (formerly CambridgeSoft). She also spent significant time at Accelrys, progressing from informatics applications support into product-marketing leadership and then senior product management for a broad portfolio spanning data content and software.

Trained as a chemist, Mariana brings a technical foundation in scientific informatics and experience across multiple disciplines, helping align platform adoption, partnerships, and operational execution across regions.

 

Bevey Miner
Company: Consensus Cloud Solutions
Title: Executive Vice President, Healthcare Strategy & Policy

Bevey Miner is Executive Vice President of Healthcare Strategy & Policy at Consensus Cloud Solutions, operating at the intersection of regulation, interoperability, and product direction. With more than 20 years in healthcare technology, she focuses on moving the industry from unstructured document exchange toward data that can be shared and acted on across care settings.

Her background spans strategy, product management, commercialization, and go-to-market leadership across both startups and publicly traded companies. Bevey has worked across payer and provider environments and has led market launches that required decisions on pricing, packaging, and positioning—experience that informs how policy changes translate into adoption realities inside healthcare organizations.

Bevey is also vocal about the “tech equity” gap: many settings such as home health, assisted living, substance use treatment, and birthing centers lack the infrastructure to send and receive structured standards like HL7/FHIR, even as policy accelerates in that direction. She earned a bachelor’s degree in journalism from Arizona State University’s Walter Cronkite School of Journalism and Mass Communication and completed Harvard Business School Executive Education.

 

Becky Blake
Company: CorroHealth
Title: Chief People Officer

Becky Blake is Chief People Officer at CorroHealth, leading the company’s people strategy across talent management, total rewards, employee relations, and organizational change. She partners with business leaders to align workforce planning and operating model decisions with business goals, with experience guiding teams through periods of growth and integration.

Before CorroHealth, Becky held senior leadership roles spanning service delivery and human resources, including senior director of service delivery at nThrive and director of human resources at Adreima. Across those roles, she built and scaled people programs, supported operational leaders, and led change initiatives tied to policy design, performance, and retention. Becky earned a bachelor’s degree in family and consumer sciences from Illinois State University.

 

Julie Sawyer Montgomery
Company: Danaher
Title: Executive Vice President, Diagnostics

Julie Sawyer Montgomery is the Executive Vice President of Diagnostics at Danaher, where she leads strategy and operational performance across the company’s global diagnostics platform. She oversees more than 18,000 associates spanning Beckman Coulter Diagnostics, Cepheid, Leica Biosystems, Mammotome, Radiometer, and HemoCue. In this role, Julie focuses on advancing disease-driven innovation while scaling technologies that expand access to high-quality diagnostic care worldwide.

Julie joined Danaher in 2017 through Beckman Coulter Diagnostics, progressing from senior commercial and R&D leadership roles to president, and later to group executive before stepping into her current EVP position. Her career reflects a consistent ability to drive growth in complex healthcare organizations, shaped by earlier leadership roles at Hospira Infusion Systems (a Pfizer company), as well as marketing strategy work at Boston Scientific and healthcare consulting at The Boston Consulting Group.

In 2025, Danaher had a strong year of diagnostics momentum, contributing to full-year revenue of approximately $24.6 billion and supporting major platform advancements. This included FDA clearance of Cepheid’s Xpert GI Panel, which strengthened Danaher’s diagnostic capabilities across hospital and laboratory settings. Julie holds a bachelor’s degree in economics from Columbia University, a master of music from the Eastman School of Music, and an MBA from Harvard Business School.

 

Kyna Fong
Company: Elation Health
Title: CEO & Co-Founder

Kyna Fong is the CEO and Co-Founder of Elation Health. She leads the company’s mission to strengthen independent primary care through clinical-first technology. Since co-founding Elation in 2010, Kyna has focused on building tools that help clinicians deliver high-value, personalized care. This work today supports tens of thousands of clinicians caring for millions of patients nationwide.

In August 2025, Kyna oversaw Elation’s expansion of its clinical-first AI platform, with AI-enabled workflow tools built natively into the EHR. The release focused on everyday primary care work—helping streamline documentation and routine tasks to reduce administrative load inside the core clinician workflow. It also signaled Elation’s product direction for making AI a standard part of how independent practices use the platform.

Trained as a health economist, Kyna holds a bachelor’s degree in applied mathematics from Harvard University, a master’s degree in computer science from Harvard, and a PhD in economics from Stanford University, where she later served as a tenure-track professor. She is also a Robert Wood Johnson Foundation Scholar in Health Policy at UC Berkeley and UCSF, grounding her leadership in both academic rigor and frontline healthcare experience.

 

Jennifer Aquino
Company: Endpoint Clinical
Title: Chief Operating Officer

Jennifer Aquino serves as Chief Operating Officer of Endpoint Clinical, where she leads operational strategy, technology, and delivery for the company’s global Randomization and Trial Supply Management (RTSM) platform. With more than 30 years of experience across eClinical systems and drug development, Jennifer is known for scaling complex operations, strengthening delivery excellence, and translating innovation into dependable execution for clinical trial sponsors worldwide.

In her role, Jennifer oversees the teams responsible for building and running Endpoint’s RTSM solutions. In 2025, she helped guide a major company milestone with Endpoint’s brand evolution and expanded RTSM capabilities.

Before joining Endpoint, Jennifer held senior leadership roles at IQVIA, Cenduit, Shire, and Parexel, where she led global technology, digital patient solutions, and operational transformation initiatives. Across each organization, her work centered on modernizing clinical systems and improving how trials are delivered at scale.

Jennifer studied business administration and management at Lesley University. Beyond her executive responsibilities, she is an active mentor in the life sciences community, supporting emerging leaders and advancing a more inclusive, forward-thinking clinical technology landscape.

 

Betty Jean Swartz
Company: Esperion
Title: Chief Business Officer

Betty Jean Swartz serves as Chief Business Officer at Esperion. In her role, she leads corporate strategy, market access, and value development. With more than 30 years of experience across pharma and biotech, Betty Jean brings deep expertise in payer strategy, health economics, government affairs, and corporate planning.

Since joining Esperion in 2021, she has overseen the organization’s strategic vision and innovative capabilities, driving brand cohesion, message alignment, and global market access initiatives while spearheading enterprise-wide strategic planning. In October 2025, she helped guide Esperion through a pivotal milestone with the company’s $75 million equity raise, strengthening resources to support ongoing development and commercialization efforts.

Earlier in her career, Betty Jean held senior commercial leadership roles at Wyeth Pharmaceuticals and later led market access and policy functions across companies including Celgene, Portola, Kaleo, Agios, and Auxilium. She also founded her own boutique market access consultancy.

Betty Jean earned a bachelor’s degree in English from the University of North Carolina at Charlotte, holds a master of organizational leadership from Cabrini University, and completed executive studies at UVA’s Darden School of Business. 

 

Vilma Durante
Company: Gedeon Richter
Title: Vice President and Head of the Global Fertility Hub

Vilma Durante serves as Vice President and Head of the Global Fertility Hub at Gedeon Richter, leading global fertility strategy within the company’s Women’s Healthcare portfolio. Based in Geneva, she oversees multifunctional teams across marketing, scientific affairs, business development, patient communications, and market access, aligning global plans with regional execution.

With more than 30 years of international leadership experience, Vilma brings deep expertise in fertility, benign gynecological conditions, and women’s health commercialization. Since joining Richter in 2016, she has played a central role in strengthening the company’s Fertility franchise, including supporting major business development initiatives and guiding strategic launches across multiple regions.

In 2025, Richter’s Women’s Healthcare business delivered double-digit revenue growth, reinforcing Fertility and gynecology as key strategic pillars and reflecting the momentum behind Vilma’s global hub model.

Earlier in her career, Vilma spent 19 years at Serono (later Merck Serono), including five years as global marketing director for fertility, before leading European Commercial Operations for Fertility and Obstetrics at Ferring Pharmaceuticals. Vilma completed executive studies in business administration and management at IMD and London Business School.

 

Laura Tomaino
Company: Glooko
Title: Chief People Officer

Laura Tomaino is the Chief People Officer of Glooko. Her focus is to build connection, alignment, and trust across a global workforce supporting millions of people living with diabetes. A seasoned HR executive, Laura focuses on scaling high-performing teams, strengthening culture, and partnering closely with leadership to ensure employees remain engaged as the business expands its connected care platform.

Since joining Glooko in September 2024, Laura has brought a data-driven, employee-first approach to talent development and organizational effectiveness. Earlier in her career, she held progressive leadership roles at HealthEdge, including SVP of people and culture, where she supported the organization through multiple stages of growth. 

Known for her belief that culture powers everything, she is an early adopter of research-backed people practices and a trusted partner to executives navigating change. Laura earned a bachelor’s degree in business administration from Saint Anselm College and a master’s degree from Harvard Extension School.

 

Chelsea Habermas
Company: Heard
Title: SVP of Operations

Chelsea Habermas serves as Senior Vice President of Operations at Heard, where she leads the systems and teams that power the company’s technology-enabled platform for therapists and private-practice providers. Overseeing provider onboarding, bookkeeping, tax operations, compliance, and service delivery, she focuses on building scalable, data-driven operations that improve accuracy, efficiency, and the provider experience.

Since joining Heard in 2023, Chelsea has played a central role in strengthening the company’s operational foundation, helping translate complex, high-volume workflows into streamlined models that support thousands of healthcare professionals nationwide. In late 2025, she was promoted to SVP of Operations, marking a key milestone in Heard’s growth as the company doubled down on automation, service quality, and infrastructure to better support its expanding provider community.

Earlier in her career, Chelsea held senior operations leadership roles across healthcare and technology organizations, including Mindful, Wheel, Lime, and Southtree, where she consistently built high-performing teams and scaled operational programs in fast-moving environments. Chelsea earned a bachelor’s degree in elementary education and teaching from Abilene Christian University.

 

Erin Curry
Company: Immunis
Title: Director of Medical Affairs

As Director of Medical Affairs at Immunis, Erin Curry oversees medical strategy and clinical research supporting regenerative therapy development for age-related disease. Erin is a board-certified Physician Assistant and applies a patient-centered approach across clinical planning and external medical engagement. Her work also reflects a focus on access for underserved populations.

Erin joined Immunis in its early days and has played a key role in shaping the company’s clinical priorities and culture. She is a core member of the team advancing IMM01-STEM, Immunis’ multi-active, cell-free biologic, supporting FDA-approved Phase 2 clinical trials across indications, including sarcopenia, osteoarthritis, and metabolic dysfunction. In 2025, she helped drive progress on Immunis’ placebo-controlled Phase 2 study in adults with sarcopenic obesity. This was an important milestone that expanded the IMM01-STEM pipeline and strengthened the company’s position in regenerative medicine.

Earlier in her clinical career, Erin worked in neurosurgery at Hoag Hospital and in neuro-oncology at St. Jude Medical Center, where she served as a sub-investigator on multiple clinical trials. Her global health work includes public health research in Kathmandu, Nepal, focused on zoonotic disease preparedness, along with ongoing volunteer service through disaster response and community health programs. Erin earned dual master’s degrees in physician assistant studies and public health from Touro University California.

 

Rebecca Jang
Company: Inocras
Title: Chief Strategy Officer

Rebecca Jang is the Chief Strategy Officer of Inocras, overseeing corporate strategy, positioning, and growth initiatives. Her work centers on how the company translates whole-genome data into actionable insights for precision oncology. She supports strategy across clinical diagnostics, research solutions, and data platforms as Inocras expands its comprehensive cancer whole-genome analysis offerings.

Rebecca has played a central role in expanding the company’s footprint across large-scale cancer genome programs. She also builds strategic partnerships with academic institutions, pharmaceutical companies, and the broader genomics ecosystem. In 2025, she helped drive a major milestone with the launch of Inocras’s cancer foundation model trained on thousands of whole genomes. This is an AI-powered platform designed to enable genome-wide patient stratification and deepen clinically relevant insights.

Earlier in her career, Rebecca was a management consultant at McKinsey & Company, where she led life sciences launch engagements and advised biopharma organizations on go-to-market strategy, commercialization, and analytics-driven growth. She also worked on public and global health initiatives across the Middle East and Africa, contributing to programs focused on improving healthcare access in resource-limited settings. Rebecca holds a master’s degree in international development from Harvard Kennedy School and a master’s degree in economics from Korea University.

 

Marcia Blackmoore
Company: L7 Informatics
Title: Chief Commercial Officer

Marcia Blackmoore serves as Chief Commercial Officer at L7 Informatics, where she leads commercial strategy and growth initiatives, helping life sciences organizations modernize how data flows across research, development, and manufacturing. Drawing on deep experience across biopharma, cell therapy, and advanced manufacturing, Marcia focuses on aligning customer needs with L7’s unified, AI-ready data platform to accelerate digital transformation at enterprise scale.

Marcia was appointed CCO in late 2025 after previously serving as vice president of therapeutic solutions, bringing hands-on expertise from roles spanning CMC leadership, clinical supply chain, and upstream development across companies including Sanofi, Kiadis Pharma, CytoSen Therapeutics, and Janssen.

Earlier in her career, Marcia worked as a scientist in large-molecule and cell therapy programs, contributing to CAR-T and immunotherapy development. Marcia holds a master’s degree in plant molecular biology from Rutgers University and a bachelor’s degree in cellular biochemistry from the State University of New York at Plattsburgh.

 

Eliza Salerno
Company: Medical Guardian
Title: Chief Operating Officer

Eliza Salerno is the Chief Operating Officer of Medical Guardian, leading operations across the company’s direct-to-consumer and healthcare divisions. She oversees product and technology alongside core operational areas, with a focus on delivering digital health and safety solutions tailored to seniors and supporting caregivers through scalable, accessible services.

Eliza joined Medical Guardian in 2017 and has advanced through a series of increasingly senior roles—senior information technology project manager, director of project management, vice president of technical operations, and SVP of operations and product—before being named COO in September 2023. Across that progression, her work has centered on technical implementation and cross-functional execution, spanning supply chain, project management, vendor management, product management, quality assurance, training, and operational strategy to support company growth.

Before Medical Guardian, Eliza held program and project leadership roles at InSight Health and Wellness and StoneBridge Wellness, managing initiatives tied to patient acquisition and retention, team training and workflows, and revenue cycle operations, including billing for major medical and Medicare reimbursements. Eliza earned her bachelor’s degree in psychology from Rutgers University.

 

Sheetal Parmar
Company: Natera
Title: Senior Vice President, Medical Affairs (Women’s Health)

Sheetal Parmar serves as Senior Vice President of Medical Affairs for women’s health at Natera, where she helps develop the clinical and medical strategy behind the company’s women’s health portfolio. A board-certified genetic counselor focused on prenatal diagnosis and screening, she brings a practitioner’s lens to how evidence, education, and clinical support translate into real-world care.

Since joining Natera in 2013, Sheetal has progressed through roles spanning medical education and clinical genetic services, including director of medical education and senior director of clinical genetic services, before leading women’s health medical affairs.

Before Natera, Sheetal spent 11 years as the lead prenatal genetic counselor at a high-risk prenatal diagnosis clinic and cytogenetic laboratory. She earned a bachelor’s degree in molecular and cell biology from UC Berkeley and a master’s degree in genetic counseling from the University of Cincinnati. She serves on the Board of Directors of the National Society of Genetic Counselors.

 

Jackie Robinson
Company: Nonin Medical
Title: Vice President of Quality and Operations

Jackie Robinson serves as Vice President of Quality and Operations at Nonin Medical, responsible for global functions spanning quality, supply chain, manufacturing, regulatory affairs, and customer operations. She brings more than 25 years of experience across healthcare technology, with a focus on building compliant systems and improving performance across complex, multi-site operations.

Having joined Nonin in 2023, Jackie has focused on strengthening quality systems and improving operational execution across global sites, including supply chain and manufacturing readiness. Before Nonin, she held senior leadership roles at Boston Scientific, St. Jude Medical, Medtronic, and Baxter International, overseeing quality and operations across cardiovascular, renal care, medication delivery, and procedural support businesses. Her work has included operational turnarounds and continuous-improvement programs in regulated environments.

Jackie earned a bachelor’s degree in mechanical engineering from the University of Minnesota, a bachelor’s degree in general engineering technology, and associate degrees in petroleum engineering and business management from Oklahoma State University.

 

Lani Bertrand
Company: Omnicell
Title: Senior Director, Clinical Marketing & Thought Leadership

Lani Bertrand is Senior Director of Clinical Marketing & Thought Leadership at Omnicell. A licensed pharmacist, she brings a blend of clinical practice, medical affairs, solution consulting, and commercial integration experience to how Omnicell communicates and delivers medication management automation for health systems.

Lani joined Omnicell in 2020 and has held senior leadership roles spanning solution consulting, commercial integration, and clinical marketing. Her work has included leading clinical consulting teams, supporting customer transitions from legacy platforms to newer systems and advanced automation services, and contributing to cross-functional efforts tied to Omnicell’s advanced services and Specialty Pharmacy Services segment. She has also supported pipeline and pro forma work and evaluated M&A opportunities aligned with commercial channels.

Before Omnicell, Lani spent nearly four years at Pacira BioSciences in medical affairs leadership roles, including leading national and regional MSL teams. Earlier, she spent close to two decades in health-system pharmacy and held pharmacy advisory and executive roles at MedAssets and Vizient. She earned her bachelor’s degree in pharmacy from the University of Wisconsin–Madison.

 

Kyoko “Kay” Deguchi
Company: PHC Holdings Corporation
Title: Chief Executive Officer

Kay Deguchi became Chief Executive Officer of PHC Holdings in April 2024 after serving as an independent external director since 2021. She leads a global group spanning diagnostics and life sciences, diabetes management, and healthcare IT, with operating companies and brands that include Ascensia, Epredia, PHCbi, PHC IVD, Wemex, LSI Medience, and Mediford.

Early in her tenure, Kay introduced PHC Group’s Value Creation Plan 2027, a mid-term management plan covering FY2024 through FY2027 and anchored in a vision focused on precision technology. The plan lays out a two-phase approach, with Phase 1 centered on structural reforms to strengthen the profit base, tighter portfolio management using ROIC, and increased emphasis on Diagnostics & Life Sciences as a growth domain. Kay also prioritized internal alignment, holding roundtables with more than 500 employees across PHC Group subsidiaries during her first months as CEO.

Under her leadership, PHC reported its highest revenue since its IPO in FY2024 alongside a sharp increase in operating profit. In March 2025, PHC announced new production technology developed with Cyfuse Biomedical that combines bio-3D printing with PHC’s LiCellGrow system to enable more stable manufacturing and real-time monitoring of three-dimensional cell products, supporting cell therapy research and development workflows. Kay earned a law degree from the University of Tokyo and an MBA from Harvard Business School.

 

Cara Melvin
Company: Reema Health
Title: Vice President of Operations

Cara Melvin serves as Vice President of Operations at Reema Health, where she leads national operations across Care Delivery, Customer Success, Finance, IT, and People. Her goal is to turn the company’s mission into scalable, day-to-day execution for tech-enabled social needs navigation and virtual mental health care. Trained as a macro practice social worker, Cara brings systems-level thinking to the practical realities of serving underserved communities, building operating models that stay human-centered while delivering measurable outcomes.

Cara began her career leading housing programs for women with severe mental illness and for young families experiencing homelessness. She then managed social services at Hennepin Healthcare—Minneapolis’s safety-net system and a Level 1 trauma center—supervising 45 social workers and developing a care model that connected population health with social determinants of health. 

Later, she led statewide programming for the Minnesota Judicial Branch across all 10 judicial districts, advancing initiatives in mental health, child welfare, and equity. Cara earned a master’s degree in macro social work from Boston University and completed a mini MBA in healthcare administration from Rutgers University.

 

Tycene Fritcher
Company: Sightview
Title: Chief Executive Officer

Tycene Fritcher is the Chief Executive Officer of Sightview, where she leads an EHR and practice management platform built for eyecare practices. With more than two decades in healthcare IT and SaaS, she has built and scaled go-to-market organizations spanning marketing, sales, and client success, with experience across both private equity- and venture-backed companies.

Since becoming CEO in June 2025, Tycene has focused on scaling Sightview’s next phase of growth by building an expanded executive team, strengthening client success programs, and leading a company-wide rebrand. Later in 2025, Sightview introduced a redesigned user experience developed with input from eyecare providers, adding workflow improvements and updated interfaces to support ophthalmology, optometry, and optician practices.

Across her career, Tycene has held senior leadership roles with full P&L responsibility and has led corporate and product strategy, positioning, and demand generation alongside sales execution and account management. She has worked across the full customer lifecycle—from initial acquisition through retention and expansion—while aligning budgets and revenue targets to operational plans.

Before Sightview, Tycene held executive roles at Nextech, SolutionReach, Avizia/Amwell, and Outcomes. She earned a bachelor’s degree in management and marketing from the University of Tampa’s John H. Sykes College of Business.

 

Jieun Choe
Company: Viz.ai
Title: Chief Operating Officer

Jieun Choe is the Chief Operating Officer of Viz.ai, leading cross-functional teams spanning product, marketing, and operations. As COO, she is turning the company’s mission to accelerate access to life-saving treatment into scalable execution across AI-powered clinical workflows. With more than two decades at the intersection of healthcare and technology, she brings deep expertise in product strategy, market adoption, and operational excellence to help Viz.ai translate innovation into real-world impact for clinicians and patients.

Before joining Viz.ai, Jieun was chief strategy and marketing officer at Certara, and earlier held strategy and product leadership roles at Guidant and Boston Scientific. At Viz.ai, she has been instrumental in strengthening strategic positioning and expanding adoption of AI-driven solutions that improve care coordination and clinical decision-making.

Jieun stepped into the COO role in September 2025, consolidating product, marketing, and execution under a unified leadership model to support the company’s next phase of scale and platform expansion. She earned a bachelor’s degree in public policy and economics from Stanford University and an MBA from Stanford Graduate School of Business.

 

Stacey Yount
Company: WCG
Title: Chief Growth Officer

Stacey Yount is the Chief Growth Officer of WCG, guiding the company’s long-term growth strategy and commercial team supporting clinical research. Her background spans more than 25 years across life sciences, including pharma, CROs, and clinical technology, with leadership roles that combine operational ownership with go-to-market execution.

Before joining WCG, Stacey served at Labcorp as senior vice president and head of global commercial, responsible for a $3.5 billion new orders target. She also helped lead the spin-off of Labcorp’s CRO business, Fortrea. Earlier, she led clinical operations and data sciences initiatives at Medidata Solutions, including work on AI-driven products and commercial and operational performance. She has also held senior roles at Covance and Eli Lilly focused on clinical operations, data management, and statistical sciences.

Stacey holds a master’s degree in audiology from Indiana University Bloomington and a Six Sigma Black Belt. She also supports the Desert Rose Foundation and Indiana University’s Life Sciences MBA program as a guest lecturer.

 

Catherine Brown
Company: Welldoc
Title: Vice President of Clinical Services

Catherine Brown is the Vice President of Clinical Services at Welldoc, overseeing clinical strategy across the company’s AI-enabled digital health portfolio and leading human factors and product research. A Registered Dietitian with more than two decades of experience, she brings expertise in nutrition, diabetes education, and patient-centered care to Welldoc’s work in cardiometabolic health.

Catherine previously held leadership roles at the University of Maryland Medical Center, including directing diabetes education programs, and has supported national diabetes education initiatives tied to the NIH and CDC. At Welldoc, she guides cross-functional teams through clinical validation, usability engineering, and risk management, helping ensure products meet clinical standards and work in real-world use. She also shapes clinical content and coaching experiences that translate patient data into practical lifestyle guidance.

Catherine’s work spans clinical innovation across regulated digital health products, including usability engineering, risk management, and support for 510(k) submissions. She earned a master’s degree in community health education from Towson University and a bachelor’s degree in dietetics from the University of Dayton.

 

Amy King
Company: Relias
Title: Chief Marketing Officer

Amy King serves as Chief Marketing Officer of Relias, where she leads a 100+ person marketing organization shaping how the company supports healthcare learning, performance, compliance, quality, and recruiting at scale. With responsibility for translating complex technology into clear value, Amy has been central to Relias’ evolution from a point-solution provider into a connected workforce enablement platform serving 13,000 healthcare organizations and 4.5 million caregivers.

Amy joined Relias in 2021 and has since built a modern, data-driven marketing engine that operates as a connective hub across Product, Sales, RevOps, Customer Success, and Data & AI. Her leadership emphasizes shared goals, common performance metrics, and measurable impact, while fostering a culture of empowerment and experimentation. In 2025, Amy’s team supported continued platform momentum as Relias expanded real-world impact through new healthcare partnerships, including a collaboration with OCH Regional Medical Center to strengthen access to patient-centered medical services.

Before Relias, Amy held senior marketing roles at Vanguard Software, Zaloni, Pixalate, MaxPoint, and Ghostery. She holds a bachelor’s degree in art history from Davidson College, a master’s degree from the University of North Carolina at Chapel Hill, and completed executive education in strategy at Harvard Business School.

 

Sophie Ruddock
Company: Empathy
Title: Chief Operating Officer

Sophie Ruddock is the Chief Operating Officer of Empathy, overseeing commercial operations and strategic growth initiatives. With 15 years of experience building and scaling technology organizations, she focuses on the teams, processes, and partnerships that expand Empathy’s reach while keeping execution consistent as the company grows.

She brings well over a decade of experience scaling high-growth technology organizations across the UK, U.S., and Europe. Before joining Empathy, Sophie was a founding executive and COO at Multiverse, where she helped grow the company from an early-stage startup into an international market leader. She spearheaded U.S. market entry, built strategic partnerships with Fortune 500 companies, and guided the organization through rapid expansion and category definition. She also advises venture-backed companies on go-to-market strategy, operational excellence, and AI innovation.

In 2025, Sophie joined Empathy during a major momentum phase, as the company reported 300% revenue growth, expanded access to more than 45 million people, and scaled partnerships with eight of the top ten U.S. life insurance carriers while handling one in five U.S. life insurance claims. Sophie earned a bachelor’s degree in social and political science from the University of Bristol.

 

Jill Johnston
Company: WCG
Title: Chief Innovation Officer

Jill Johnston is the Chief Innovation Officer of WCG. In her role, Jill drives innovation and integration across the organization, working with teams to identify, scale, and operationalize new approaches across clinical development services and technology. She also leads business transformation and strategy efforts tied to emerging processes, tools, and client delivery models.

Previously, Jill served as president of WCG’s study planning and site solutions. Her background also includes serving as vice president of clinical strategy at Veeva Systems, where she contributed to strategy for the Veeva Vault Clinical Suite. Prior to Veeva, she spent more than two decades at Covance, including leadership roles in global transformation programs and site activation, informatics, and trial optimization, with experience overseeing pivotal Phase II and III clinical trials across multiple therapeutic areas.

Jill holds a bachelor’s degree in environmental and forest biology from SUNY’s College of Environmental Science and Forestry and an associate’s degree in biology from SUNY Cobleskill. She has also served as an instructor in clinical research and clinical development programs and is a member of the board of directors at Inspire.